Verily, Alphabet’s life sciences company, has reduced staff and closed its long-running devices program while narrowing its strategic focus toward AI and infrastructure. The devices program included projects such as a clinical study watch, a retinal camera, and a partnership with Dexcom on a wearable glucose sensor. Longtime employees in Devices invested years or decades in developing medical hardware. Verily has been streamlining and simplifying operations since 2023 to prioritize areas with greater commercial impact. Manufacturing of medical devices will be discontinued and resources will be reallocated to initiatives aligned with the refocused strategy.
"The path forward requires difficult decisions," he wrote.
"Over the years, Verily has built a legacy in developing world-class, innovative medical devices,"
"The dedicated professionals in our Devices organizations - many who have devoted a decade or more to this important work - have poured their hearts, expertise, and commitment into advancing healthcare technology."
"As part of normal business operations, we continue to make deliberate choices about resourcing where we can have the greatest impact and to put ourselves on a faster path to sustained commercial success,"
Collection
[
|
...
]